Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
75
Participants
Timeline
Start Date
September 30, 2015
Primary Completion Date
January 31, 2018
Study Completion Date
February 28, 2018
Conditions
Type 2 Diabetes MellitusDiabetes
Interventions
BIOLOGICAL
REMD-477
Trial Locations (3)
Unknown
Miami
San Antonio
Renton
All Listed Sponsors
lead
REMD Biotherapeutics, Inc.
INDUSTRY
NCT02455011 - Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter